Epidiolex cannabidiol

The sucralose excipient controversy is an under-the-radar adherence and trust killer that patient communities are amplifying loudly, creating a concrete formulation-linked churn risk Jazz can address now.

• Seizure reduction drives strong positive sentiment in responders, but roughly one-third of families report no meaningful benefit or outright worsening, making response heterogeneity the single biggest trust barrier at initiation.
• The sucralose excipient is a recurring, patient-initiated complaint tightly linked to GI side effects and gut-health concerns, representing a formulation-specific unmet need absent from any competitor label.
• Caregiver-reported secondary gains (improved cognition, communication, sleep, and behavior) are powerful loyalty drivers that are systematically undercommunicated by the brand relative to seizure-frequency data alone.
• Access friction (prior authorization, specialty pharmacy logistics, and high out-of-pocket cost) creates a gap between neurologist recommendation and first dose that peers and patient services can close.